JP2011500601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500601A5 JP2011500601A5 JP2010529095A JP2010529095A JP2011500601A5 JP 2011500601 A5 JP2011500601 A5 JP 2011500601A5 JP 2010529095 A JP2010529095 A JP 2010529095A JP 2010529095 A JP2010529095 A JP 2010529095A JP 2011500601 A5 JP2011500601 A5 JP 2011500601A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorotoxin
- cancer
- agent
- chlorotoxin agent
- labeled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 claims 84
- 101710164760 Chlorotoxin Proteins 0.000 claims 81
- 229960005534 chlorotoxin Drugs 0.000 claims 81
- 239000003795 chemical substances by application Substances 0.000 claims 66
- 206010028980 Neoplasm Diseases 0.000 claims 39
- 210000001519 tissue Anatomy 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 9
- 229940127089 cytotoxic agent Drugs 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 239000002254 cytotoxic agent Substances 0.000 claims 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 238000002372 labelling Methods 0.000 claims 5
- 208000032612 Glial tumor Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 206010027191 meningioma Diseases 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- 238000007910 systemic administration Methods 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 241000196324 Embryophyta Species 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 2
- 201000005746 Pituitary adenoma Diseases 0.000 claims 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 2
- 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010046431 Urethral cancer Diseases 0.000 claims 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 201000005969 Uveal melanoma Diseases 0.000 claims 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 2
- 229930013930 alkaloid Natural products 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 239000000051 antiandrogen Substances 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 229940046844 aromatase inhibitors Drugs 0.000 claims 2
- 230000008512 biological response Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 230000032823 cell division Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 claims 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 2
- 229940044173 iodine-125 Drugs 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 201000002575 ocular melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000005298 paramagnetic effect Effects 0.000 claims 2
- 208000028591 pheochromocytoma Diseases 0.000 claims 2
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 2
- 238000002600 positron emission tomography Methods 0.000 claims 2
- 239000000649 purine antagonist Substances 0.000 claims 2
- 239000003790 pyrimidine antagonist Substances 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000003708 skin melanoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 229940056501 technetium 99m Drugs 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 102000000989 Complement System Proteins Human genes 0.000 claims 1
- 108010069112 Complement System Proteins Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 101710183280 Topoisomerase Proteins 0.000 claims 1
- 230000003388 anti-hormonal effect Effects 0.000 claims 1
- 239000013059 antihormonal agent Substances 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 210000003763 chloroplast Anatomy 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 230000001293 nucleolytic effect Effects 0.000 claims 1
- 108700028325 pokeweed antiviral Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000011453 reproductive organ cancer Diseases 0.000 claims 1
- 208000015608 reproductive system cancer Diseases 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 201000000360 urethra cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97971407P | 2007-10-12 | 2007-10-12 | |
| PCT/US2008/079547 WO2009049184A2 (en) | 2007-10-12 | 2008-10-10 | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011500601A JP2011500601A (ja) | 2011-01-06 |
| JP2011500601A5 true JP2011500601A5 (enExample) | 2011-11-17 |
Family
ID=40549847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529095A Pending JP2011500601A (ja) | 2007-10-12 | 2008-10-10 | 腫瘍の診断および処置のためのクロロトキシン薬剤の全身性投与 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100215575A1 (enExample) |
| EP (1) | EP2211913A4 (enExample) |
| JP (1) | JP2011500601A (enExample) |
| CN (1) | CN101918041A (enExample) |
| AU (1) | AU2008310664A1 (enExample) |
| CA (1) | CA2702314A1 (enExample) |
| WO (1) | WO2009049184A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2360519T3 (es) * | 2005-04-22 | 2011-06-06 | University Of Washington | Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer. |
| WO2009140599A1 (en) | 2008-05-15 | 2009-11-19 | Transmolecular, Inc. | Treatment of metastatic tumors |
| CN106995493B (zh) | 2010-02-04 | 2021-09-24 | 卫材公司 | 氯毒素多肽和结合物及其应用 |
| EP3165533B1 (en) | 2010-05-11 | 2020-04-08 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates and methods for their use |
| CN101804197B (zh) * | 2010-05-21 | 2012-05-23 | 魏华 | 一种用于癌症骨转移的药物组合物及其用途 |
| US8524239B2 (en) | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
| US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
| CN102552943A (zh) * | 2010-12-31 | 2012-07-11 | 复旦大学 | 一种氯代毒素修饰的肿瘤靶向磁共振造影剂及其制备方法和应用 |
| CA2824154A1 (en) | 2011-01-10 | 2012-07-19 | President And Fellows Of Harvard College | Method for delivering agents into cells using bacterial toxins |
| WO2013009655A2 (en) | 2011-07-08 | 2013-01-17 | Sloan-Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
| CN104039805B (zh) | 2011-12-22 | 2016-11-16 | 糖模拟物有限公司 | E-选择蛋白拮抗剂化合物、组合物及使用方法 |
| JP6187960B2 (ja) * | 2012-01-20 | 2017-08-30 | 日本製粉株式会社 | がんの治療又は予防剤 |
| EP2817341A4 (en) | 2012-02-23 | 2015-12-02 | Harvard College | MICROBIAL MODIFIED TOXIN RECEPTOR FOR THE DISTRIBUTION OF AGENTS IN CELLS |
| SI2928476T1 (en) | 2012-12-07 | 2018-06-29 | Glycomimetics, Inc. | COMPONENTS, INSTALLATIONS AND PROCEDURES OF THE APPLICATION OF E-SELECTINE OF ANTAGONISTS FOR THE MOBILIZATION OF HEMATOPOETIC CELLS |
| BR112015013525A2 (pt) | 2012-12-10 | 2017-11-14 | Hutchinson Fred Cancer Res | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| EP3718570A1 (en) * | 2014-06-02 | 2020-10-07 | Li-Cor, Inc. | Phthalocyanine probes and uses thereof |
| EP3177323B2 (en) | 2014-08-08 | 2023-01-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Photo-controlled removal of targets in vitro and in vivo |
| JP6689854B2 (ja) | 2014-12-03 | 2020-04-28 | グリコミメティクス， インコーポレイテッド | Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤 |
| WO2017031363A2 (en) | 2015-08-18 | 2017-02-23 | Aspyrian Therapeutics, Inc. | Methods for manufacturing phthalocyanine dye conjugates and stable conjugates |
| US11090358B2 (en) | 2015-09-09 | 2021-08-17 | Fred Hutchinson Cancer Research Center | Cartilage-homing peptides |
| WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
| CA3021011A1 (en) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| WO2018031445A1 (en) | 2016-08-08 | 2018-02-15 | Glycomimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4 |
| KR102653723B1 (ko) | 2016-10-07 | 2024-04-01 | 글리코미메틱스, 인크. | 매우 강력한 다량체성 e-셀렉틴 길항물질 |
| WO2018136614A1 (en) | 2017-01-18 | 2018-07-26 | Fred Hutchinson Cancer Research Center | Peptide compositions and methods of use thereof for disrupting tead interactions |
| JP7272956B2 (ja) | 2017-03-15 | 2023-05-12 | グリコミメティクス， インコーポレイテッド | Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体 |
| CN110475565A (zh) | 2017-03-16 | 2019-11-19 | 光明之火生物科学公司 | 软骨归巢肽缀合物及其使用方法 |
| EP3638290A4 (en) | 2017-06-15 | 2021-04-07 | Blaze Bioscience, Inc. | KIDNEY HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF |
| JP7409741B2 (ja) | 2017-09-15 | 2024-01-09 | エーザイ インク． | クロロトキシン薬剤及びその使用 |
| US11712446B2 (en) | 2017-11-30 | 2023-08-01 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
| US11866466B2 (en) | 2017-12-19 | 2024-01-09 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
| BR112020013198A2 (pt) | 2017-12-29 | 2020-12-01 | Glycomimetics, Inc. | inibidores heterobifuncionais de e-selectina e galectina-3 |
| US11707474B2 (en) | 2018-03-05 | 2023-07-25 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
| WO2020139962A1 (en) | 2018-12-27 | 2020-07-02 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
| US20240115717A1 (en) | 2020-12-30 | 2024-04-11 | Vrg Therapeutics Kft. | Chlorotoxin derivatives and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5905027A (en) * | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
| US6667156B2 (en) * | 1995-12-27 | 2003-12-23 | Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| DE60331458D1 (de) * | 2002-05-31 | 2010-04-08 | Transmolecular Inc | Kombinationschemotherapie mit chlorotoxin |
| US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
| ES2360519T3 (es) * | 2005-04-22 | 2011-06-06 | University Of Washington | Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer. |
| EP2147927A3 (en) * | 2006-03-31 | 2010-09-01 | Transmolecular, Inc. | Use of 131i-tm-601 for the diagnosis and treatment of gliomas |
| US20090004105A1 (en) * | 2007-06-27 | 2009-01-01 | Zhen Cheng | Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin |
| WO2009140599A1 (en) * | 2008-05-15 | 2009-11-19 | Transmolecular, Inc. | Treatment of metastatic tumors |
-
2008
- 2008-10-10 CA CA2702314A patent/CA2702314A1/en not_active Abandoned
- 2008-10-10 JP JP2010529095A patent/JP2011500601A/ja active Pending
- 2008-10-10 CN CN2008801112420A patent/CN101918041A/zh active Pending
- 2008-10-10 EP EP08837002A patent/EP2211913A4/en not_active Withdrawn
- 2008-10-10 US US12/682,692 patent/US20100215575A1/en not_active Abandoned
- 2008-10-10 WO PCT/US2008/079547 patent/WO2009049184A2/en not_active Ceased
- 2008-10-10 AU AU2008310664A patent/AU2008310664A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500601A5 (enExample) | ||
| JP2011520914A5 (enExample) | ||
| Kassis | The amazing world of auger electrons | |
| Fani et al. | In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates | |
| Leamon et al. | Synthesis and biological evaluation of EC20: a new folate-derived, 99mTc-based radiopharmaceutical | |
| AU2003239383B2 (en) | Vitamin-targeted imaging agents | |
| Muller | Folate based radiopharmaceuticals for imaging and therapy of cancer and inflammation | |
| Gourni et al. | N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga-and 64Cu-labeled peptides for PET imaging | |
| US20170319721A1 (en) | Alpha-emitting complexes | |
| Müller et al. | Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting | |
| Müller et al. | SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate | |
| Pettenuzzo et al. | Vitamin B12–metal conjugates for targeted chemotherapy and diagnosis: Current status and future prospects | |
| Jin et al. | αVβ3 Integrin-targeted radionuclide therapy with 64Cu-cyclam-RAFT-c (-RGDfK-) 4 | |
| Müller et al. | Single photon emission computed tomography tracer | |
| Müller et al. | Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors | |
| bin Othman et al. | In vitro cytotoxicity of Auger electron-emitting [67Ga] Ga-trastuzumab | |
| Wayua et al. | Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor–expressing cancers | |
| JP2017503763A5 (enExample) | ||
| Aljammaz et al. | Development and pre-clinical evaluation of new 68Ga-NOTA-folate conjugates for PET imaging of folate receptor-positive tumors | |
| Müller et al. | Tumor targeting using 67Ga-DOTA-Bz-folate—investigations of methods to improve the tissue distribution of radiofolates | |
| Fani et al. | Development of new folate-based PET radiotracers: preclinical evaluation of 68Ga-DOTA-folate conjugates | |
| Zhang et al. | An aptamer-based, fluorescent and radionuclide dual-modality probe | |
| Fang et al. | Preclinical advances in theranostics for the different molecular subtypes of breast cancer | |
| Farzin et al. | Clinical aspects of radiolabeled aptamers in diagnostic nuclear medicine: A new class of targeted radiopharmaceuticals | |
| JP2020504130A5 (enExample) |